These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27882776)

  • 1. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
    Wei L; Kao JH
    Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
    Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
    J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabtake S; Ito T
    J Gastroenterol; 2015 Jul; 50(7):795-804. PubMed ID: 25376770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis.
    Zhang QQ; An X; Liu YH; Li SY; Zhong Q; Wang J; Hu HD; Zhang DZ; Ren H; Hu P
    Virol J; 2011 Feb; 8():72. PubMed ID: 21324130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
    Hiramatsu N; Yamada R; Takehara T
    J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
    Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
    Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
    Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.
    Moon JC; Kim SH; Kim IH; Lee CH; Kim SW; Lee SO; Lee ST; Kim DG
    Gut Liver; 2015 May; 9(3):395-404. PubMed ID: 25473072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
    Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
    Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
    Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.